Tapentadol, Buprenorphine, and Levorphanol for the Treatment of Neuropathic Pain: a Systematic Review
| Autor: | Amitabh Gulati, Samantha C Erosa, Paul Ryan Haffey, Neel Mehta |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pain medicine
law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial 030202 anesthesiology law medicine Humans Levorphanol Randomized Controlled Trials as Topic business.industry General Medicine Tapentadol medicine.disease Low back pain Buprenorphine Analgesics Opioid Treatment Outcome Anesthesiology and Pain Medicine Peripheral neuropathy Anesthesia Neuropathic pain Neuralgia Neurology (clinical) medicine.symptom business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Current Pain and Headache Reports. 25 |
| ISSN: | 1534-3081 1531-3433 |
| Popis: | The objective of this systematic review is to present the available evidence for the utilization of the atypical opioids tapentadol, buprenorphine, and levorphanol for the treatment of neuropathic pain. In total, 1619 articles were retrieved of which 10 studies were included. Of 5 included studies pertaining to tapentadol, 4 studies show tapentadol monotherapy to be effective for the treatment of diabetic peripheral neuropathy or chronic, radiating low back pain. Of the 3 studies included for buprenorphine, only one was a randomized controlled trial found not to have a statistically significant reduction in pain with TD buprenorphine likely due to very high withdrawal rates during the trial. Only 2 case reports were included from the available literature for levorphanol providing low-quality anecdotal evidence. The role of tapentadol, buprenorphine, and levorphanol for neuropathic pain conditions requires robust research including randomized controlled trials to evaluate their efficacy and safety. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink